Nicolas Widmer

Imatinib plasma concentrations variability in oncologic patients

Is imatinib a candidate drug for a therapeutic drug monitoring program?

• Broschiertes Buch

Produktbeschreibung

The anticancer drug imatinib has transformed the treatment and prognosis of chronic myeloid leukemia and gastrointestinal stromal tumor. However, the treatment must be taken indefinitely and is not devoid of inconveniences and toxicity. Moreover, resistance or escape from disease control are occurring. Considering the large interindividual differences in the function of the enzymatic and transport systems involved in imatinib disposition, exposure to this drug can be expected to vary widely among patients. This book describes an observational clinical trial aiming at exploring the influence of these covariates on imatinib pharmacokinetics and assessing the interindividual variability of the pharmacokinetic parameters of the drug. A large interindividual variability was observed, together with some preliminary concentration-effect relationships. These elements are arguments to further investigate the potential benefit of a therapeutic drug monitoring program to optimize the use ofimatinib in patients. Such results should be especially useful to clinical oncologists or scientists involved in clinical oncology research.

Produktdetails

• Verlag: LAP Lambert Academic Publishing
• Seitenzahl: 248
• Erscheinungstermin: 18. August 2010
• Englisch
• Abmessung: 220mm x 150mm x 15mm
• Gewicht: 387g
• ISBN-13: 9783838385112
• ISBN-10: 383838511X
• Artikelnr.: 31809964

Autorenporträt

is a Swiss pharmacist who specialized both in Hospital Pharmacy and Clinical Pharmacology, and gained his PhD in Life Sciences in 2006. He is at present in charge of the Therapeutic Drug Monitoring service at the Division of Clinical Pharmacology and Toxicology (University Hospital Center and University of Lausanne).